Evidence map›Paper›PMID 42483203›Full record

ArticleFrontiers in immunology2026

BAG3

Jing Sun, Zhengqi Cao, Yueping Jin, Anni Wang, Li Lu, Lixuan Chen, Wenhui Shi, Peiyi Xu, Yuxin Ouyang, Junjie Tang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jing Sun *Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Zhengqi Cao *Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Yueping Jin *Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Anni WangDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Li LuDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Lixuan ChenDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Wenhui ShiDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Peiyi XuDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Yuxin OuyangDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Junjie TangDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Zhouwenli MengDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.
Ziming LiDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine;Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite significantly improving outcomes in non-small cell lung cancer (NSCLC), neoadjuvant chemoimmunotherapy (NCIT) fails to achieve a major pathological response (MPR) in over 40% of patients. Consequently, the early identification of non-responders prior to treatment initiation remains a critical unmet clinical need. Methods: In this study, we performed single-cell RNA sequencing (scRNA-seq) on pre-treatment NSCLC tissue samples and integrated data from two public databases to identify signaling pathways associated with poor treatment response. Key findings were subsequently validated using multiplex immunofluorescence (mIF), and the predictive value of identified molecules was finally assessed in our cohort and GEO datasets. Results: Among the 83 patients, 23/57 (40.35%) of these radiological responders failed to achieve MPR. Data analysis revealed activation of stress-related signaling pathways in cancer-associated fibroblasts (CAFs) and T cells from nMPR patients, with elevated expression of stress-related markers, including BAG3 and IFITM2. MIF confirmed that BAG3 Conclusion: The BAG3

Indexed as

Apoptosis Regulatory ProteinsCancer-Associated FibroblastsCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsBiomarkers, TumorFemaleHumansImmunotherapyLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoadjuvant TherapyTumor MicroenvironmentApoptosis Regulatory ProteinsBiomarkers, TumorBAG3+ CAF-T cell neighborhoodbiomarkercancer-associated fibroblasts (CAFs)neoadjuvant chemoimmunotherapy (NCIT)non-small cell lung cancer (NSCLC)

Identifiers

PMID42483203
PMCPMC13385752

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.